Anlon Healthcare Limited, a pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) manufacturer based in Rajkot, Gujarat, is set to launch its Initial Public Offering (IPO). The company, founded in 2013, has established itself as a key player in the pharmaceutical manufacturing sector with strong international presence.
Key IPO Details at a Glance
| Parameter | Details |
|---|---|
| IPO Open Date | August 26, 2025 |
| IPO Close Date | August 29, 2025 |
| Price Band | ₹86 – ₹91 per share |
| Lot Size | 164 shares |
| Minimum Investment | ₹14,924 |
| Issue Size | ₹121.03 crores |
| Listing Date | September 3, 2025 |
| Listing Exchanges | BSE & NSE |
Anlon Healthcare IPO GMP (Grey Market Premium) Today
What is IPO GMP?
Grey Market Premium (GMP) is the additional amount investors are willing to pay for IPO shares in the unofficial grey market before official listing. It serves as an indicator of investor sentiment and potential listing performance.
Current Anlon Healthcare IPO GMP Status
As of August 25, 2025, the Anlon Healthcare IPO GMP stands at ₹0, indicating neutral market sentiment. This means:
- Expected Listing Price: ₹91 (upper price band)
- Estimated Listing Gains: 0% based on current GMP
- Market Sentiment: Neutral to cautious
Important Note: GMP can change rapidly based on market conditions, subscription levels, and investor sentiment. The current zero GMP suggests investors are taking a wait-and-watch approach.
GMP Trend Analysis
| Date | IPO GMP | Expected Listing Price | Estimated Gains |
|---|---|---|---|
| August 25, 2025 | ₹0 | ₹91 | 0% |
| August 24, 2025 | ₹0 | ₹91 | 0% |
| August 23, 2025 | ₹0 | ₹91 | 0% |
Read More: Vikran Engineering IPO GMP ₹18 Today! Complete Guide to Price, Dates & Allotment Status
Company Profile & Business Operations
About Anlon Healthcare Limited
Anlon Healthcare Limited is a research-intensive chemical manufacturing company specializing in high-purity pharmaceutical intermediates and APIs. The company serves both domestic and international markets with products that comply with global regulatory standards.
Key Business Areas:
- Pharmaceutical Intermediates: Raw materials for API manufacturing
- Active Pharmaceutical Ingredients (APIs): Used in tablets, capsules, ointments, syrups
- Nutraceutical APIs: For nutritional supplements
- Personal Care & Veterinary Products: Specialized ingredients
Manufacturing Excellence
The company operates from a single manufacturing facility in Rajkot, Gujarat, which is certified with:
- ISO 9001:2015
- Good Manufacturing Practice (GMP)
- WHO-GMP certification
Global Reach & Regulatory Approvals
Anlon Healthcare has achieved significant regulatory milestones:
- Drug Master File (DMF) approvals from ANVISA (Brazil), NMPA (China), and PMDA (Japan)
- 21 DMFs filed with regulatory bodies across Europe, Russia, Japan, South Korea, Iran, Jordan, and Pakistan
- International presence in over 15 countries including Italy, Germany, South Korea, China, Argentina, Chile, Colombia, Mexico, Egypt, Turkey, Japan, Brazil, UK, and UAE
Read More: Vikram Solar IPO Listing Date August 26: Check GMP, Share Price & Allotment Status
Financial Performance Analysis
Strong Growth Trajectory
Anlon Healthcare has demonstrated exceptional financial performance in recent years:
| Parameter | FY 2025 | FY 2024 | Growth |
|---|---|---|---|
| Revenue | ₹120.46 crores | ₹66.69 crores | 81% |
| EBITDA | ₹32.38 crores | ₹15.57 crores | 108% |
| Net Profit | ₹20.52 crores | ₹9.66 crores | 112% |
| Net Profit Margin | 17.06% | 14.51% | 2.55% points |
Financial Highlight: The company’s revenue growth of 81% and profit growth of 112% in FY25 demonstrates strong operational efficiency and market demand for its products.
Key Financial Ratios
| Ratio | FY 2025 | FY 2024 |
|---|---|---|
| Return on Net Worth | 25.51% | 45.92% |
| Debt-Equity Ratio | 0.73 | 3.55 |
| ROCE | 21.93% | 16.29% |
Read More: ICSI CS Result June 2025 Declared: Professional & Executive Results Out – Check Your Scores Now!
IPO Allotment Process & Timeline
Important IPO Dates
| Event | Date |
|---|---|
| IPO Opening | August 26, 2025 |
| IPO Closing | August 29, 2025 |
| Allotment Finalization | September 1, 2025 |
| Refund Initiation | September 2, 2025 |
| Shares Credit to Demat | September 2, 2025 |
| Listing Date | September 3, 2025 |
Share Reservation Pattern
| Category | Allocation |
|---|---|
| Qualified Institutional Buyers (QIB) | 75% |
| Non-Institutional Investors (HNI) | 15% |
| Retail Individual Investors | 10% |
Minimum Investment Requirements
| Investor Category | Minimum Lots | Minimum Shares | Minimum Amount |
|---|---|---|---|
| Retail Investors | 1 lot | 164 shares | ₹14,924 |
| HNI (Small) | 14 lots | 2,296 shares | ₹2,08,936 |
| HNI (Big) | 68 lots | 11,152 shares | ₹10,14,832 |
How to Check Anlon Healthcare IPO Allotment Status
Method 1: KFin Technologies (Registrar Website)
KFin Technologies Limited is the official registrar for Anlon Healthcare IPO. Follow these steps:
- Visit KFin Technologies IPO allotment page
- Select “Anlon Healthcare Limited IPO” from dropdown
- Choose search method: PAN, Application Number, or Demat Account
- Enter required details
- Submit captcha and click “Check Status”
Contact Details:
- Phone: 040-67162222, 040-79611000
- Email: ahl.ipo@kfintech.com
Method 2: BSE Website
- Visit BSE IPO allotment page (bseindia.com/investors/appli_check.aspx)
- Select “Equity” under Issue Type
- Choose “Anlon Healthcare Limited IPO” from Issue Name
- Enter Application Number and PAN
- Complete captcha and click “Search”
Method 3: NSE Website
- Go to NSE IPO allotment page
- Select “Anlon Healthcare Limited IPO” from dropdown
- Enter Application Number, PAN, and captcha
- Click “Search” to view status
Method 4: IPO Ji App/Website
- Download IPO Ji app or visit ipoji.com
- Create account with PAN and Demat details
- Select Anlon Healthcare IPO
- Click “Check Status” button
Read More: 2025 Renault Kiger: Price, Features, and All You Need to Know
IPO Objectives & Fund Utilization
Anlon Healthcare plans to utilize the ₹121.03 crore IPO proceeds for:
- Manufacturing Facility Expansion: ₹30.72 crores (25.4%)
- Working Capital Requirements: ₹43.15 crores (35.7%)
- Debt Repayment: ₹5 crores (4.1%)
- General Corporate Purposes: Remaining funds
The focus on expansion and working capital indicates the company’s growth-oriented approach and confidence in market demand.
Competitive Analysis & Peer Comparison
Industry Position
| Company | P/E Ratio | EPS (₹) | RoNW (%) | Revenue (₹ Cr) |
|---|---|---|---|---|
| Anlon Healthcare | 14.26 | 6.38 | 25.51 | 120.29 |
| Kronox Lab Sciences | 26.18 | 6.91 | 28.26 | 100.19 |
| Acutaas Chemicals | 58.47 | 19.81 | 12.15 | 1,006.88 |
| Supriya Lifesciences | 29.27 | 23.35 | 18.86 | 581.00 |
Key Observations:
- Anlon Healthcare offers attractive P/E valuation at 14.26x compared to peers
- Strong Return on Net Worth of 25.51%, outperforming most competitors
- Revenue growth potential with expanding market presence
Read More: MG Windsor EV 2025 Price, Launch Date, Features, How to Book Online in India?
Risk Factors & Investment Considerations
Strengths
- Strong Financial Performance: 81% revenue growth and 112% profit growth in FY25
- Global Regulatory Approvals: DMF approvals from major international authorities
- Diversified Product Portfolio: 65 commercialized products with strong pipeline
- Experienced Management: Led by promoters with over 11 years of industry experience
- Quality Certifications: ISO, GMP, and WHO-GMP certified facility
Risk Factors
- Single Manufacturing Location: Operations concentrated in Rajkot, Gujarat
- High Working Capital Days: 261 days in FY24, indicating cash flow challenges
- Customer Concentration Risk: Dependence on key pharmaceutical clients
- Regulatory Compliance: Strict international standards requirement
- Raw Material Price Volatility: Impact on profit margins
Investment Recommendation & Broker Views
Current Market Sentiment
The zero GMP indicates cautious investor sentiment, possibly due to:
- Recent market volatility in pharmaceutical sector
- Upcoming listing of multiple IPOs in similar timeline
- Investor preference for established players
Should You Invest?
Positive Factors:
- Strong financial growth trajectory
- Reasonable valuation compared to peers
- Growing international presence
- Experienced management team
Caution Areas:
- Zero current GMP suggests limited listing gains expectation
- Single facility operational risk
- High working capital requirements
Investment Advice: Suitable for long-term investors seeking exposure to growing pharmaceutical intermediates market. Short-term traders should monitor GMP trends and subscription levels.
Read More: Google Pixel 10 Packed With Tensor G5 AI Power, Camera Upgrades, and 7-Year Updates
Frequently Asked Questions (FAQs)
Q1: What is the current Anlon Healthcare IPO GMP?
Answer: As of August 25, 2025, the Anlon Healthcare IPO GMP is ₹0, indicating neutral market sentiment with expected listing at the upper price band of ₹91.
Q2: When will Anlon Healthcare IPO open and close?
Answer: The Anlon Healthcare IPO opens on August 26, 2025 and closes on August 29, 2025. The listing date is scheduled for September 3, 2025.
Q3: What is the minimum investment amount for Anlon Healthcare IPO?
Answer: The minimum investment is ₹14,924 for 164 shares (1 lot) at the upper price band of ₹91 per share.
Q4: How to check Anlon Healthcare IPO allotment status?
Answer: You can check allotment status on KFin Technologies website (official registrar), BSE website, NSE website, or through the IPO Ji app using your PAN, application number, or Demat account details.
Q5: What is Anlon Healthcare’s main business?
Answer: Anlon Healthcare manufactures high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) used in tablets, capsules, ointments, syrups, nutraceuticals, personal care, and veterinary products.
Q6: Is Anlon Healthcare IPO worth investing?
Answer: The company shows strong financial performance with 81% revenue growth and 112% profit growth in FY25. However, the zero GMP suggests cautious market sentiment. It may suit long-term investors seeking pharmaceutical sector exposure.
Q7: What are the IPO proceeds being used for?
Answer: The ₹121.03 crore proceeds will fund manufacturing facility expansion (₹30.72 cr), working capital (₹43.15 cr), debt repayment (₹5 cr), and general corporate purposes.
Q8: Who is the registrar for Anlon Healthcare IPO?
Answer: KFin Technologies Limited is the official registrar. Contact details: Phone: 040-67162222, Email: ahl.ipo@kfintech.com.
Disclaimer: This information is for educational purposes only and should not be considered as investment advice. Please consult your financial advisor and read the offer document carefully before making any investment decisions. IPO investments carry market risks, and past performance is not indicative of future results.
